Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025
The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.
Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.
Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.
Further Key Findings From the Study Suggest:
The growing prevalence of mental disorders, increased investments on R&D, and rising awareness regarding these conditions are augmenting the growth of the market.
The first-generation of antipsychotics have serious adverse effects and are very rarely used, hence they hold negligible share in the market.
The second-generation segment of drugs accounted for the largest share in 2015 and are anticipated to further expand during the forecast period despite the adverse effects
As of January 2016, the third-generation segment has only one approved product, Abilify. It has negligible adverse effects and is expected to be the fastest growing segment over the forecast period
In 2015, North America dominated the global space with the largest revenue share owing to rising prevalence of mental illnesses
Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding mental disorders and improving access to treatment
Some of the major players in this market are Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers Squibb
Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.
Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.
Further Key Findings From the Study Suggest:
The growing prevalence of mental disorders, increased investments on R&D, and rising awareness regarding these conditions are augmenting the growth of the market.
The first-generation of antipsychotics have serious adverse effects and are very rarely used, hence they hold negligible share in the market.
The second-generation segment of drugs accounted for the largest share in 2015 and are anticipated to further expand during the forecast period despite the adverse effects
As of January 2016, the third-generation segment has only one approved product, Abilify. It has negligible adverse effects and is expected to be the fastest growing segment over the forecast period
In 2015, North America dominated the global space with the largest revenue share owing to rising prevalence of mental illnesses
Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding mental disorders and improving access to treatment
Some of the major players in this market are Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers Squibb
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Data Analysis
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 ANTIPSYCHOTIC DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Growing prevalence of psychosis and associated disorders
3.1.1.2 Continuous investment in research and development
3.1.2 Market restraint analysis
3.1.2.1 Adverse effects and chance of habit formation
3.1.2.2 Patent expiry of major drugs
3.2 Penetration & Growth Prospect Mapping, 2016
3.3 Antipsychotics Drugs Market- PESTLE Analysis, 2016
3.4 Industry Analysis - Porter’s, 2016
3.5 Pipeline Analysis of Antipsychotic Drugs
CHAPTER 4 ANTIPSYCHOTIC DRUGS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1 Antipsychotic Drug Market: Drug Class Movement Analysis, 2016
4.2 First Generation/Standard/Typical Antipsychotics Drug
4.2.1 First generation/Standard/Typical antipsychotic drugs market estimates & forecasts, 2014 - 2025 (USD Million)
4.3 Haldol market
4.3.1 Haldol market estimates & forecasts, 2014 - 2025 (USD Million)
4.4 Navane market
4.4.1 Navane market estimates & forecasts, 2014 - 2025 (USD Million)
4.5 Other market
4.5.1 Other market estimates & forecasts, 2014 - 2025 (USD Million)
4.6 Second Generation/Atypical Antipsychotics Drug
4.6.1 Second generation/Atypical antipsychotic drugs market market estimates & forecasts, 2014 - 2025 (USD Million)
4.7 Zyprexa market
4.7.1 Zyprexa market estimates & forecasts, 2014 - 2025 (USD Million)
4.8 Seroquel market
4.8.1 Seroquel market estimates & forecasts, 2014 - 2025 (USD Million)
4.9 Risperdal market
4.9.1 Risperdal market estimates & forecasts, 2014 - 2025 (USD Million)
4.10 Invega market
4.10.1 Invega market estimates & forecasts, 2014 - 2025 (USD Million)
4.11 Latuda market
4.11.1 Latuda market estimates & forecasts, 2014 - 2025 (USD Million)
4.12 Others market
4.12.1 Other market estimates & forecasts, 2014 - 2025 (USD Million)
4.13 Third generation Antipsychotics Drug
4.13.1 Third generation antipsychotic drugs market, 2014 - 2025 (USD Million)
CHAPTER 5 ANTIPSYCHOTIC DRUGS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Antipsychotics Drugs Market: Application Movement Analysis, 2016
5.2 Schizophrenia
5.2.1 Schizophrenia market estimates & forecasts, 2014 - 2025 (USD Million)
5.3 Bipolar Disorder
5.3.1 Bipolar Disorder market estimates & forecasts, 2014 - 2025 (USD Million)
5.4 Depression
5.4.1 Depression market estimates & forecasts, 2014 - 2025 (USD Million)
5.5 Dementia
5.5.1 Dementia market estimates & forecasts, 2014 - 2025 (USD Million)
5.6 Other psychotic disorders
5.6.1 Other psychotic disorders market estimates & forecasts, 2014 - 2025 (USD Million)
CHAPTER 6 ANTIPSYCHOTIC DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY DRUG CLASS AND APPLICATION
6.1 Antipsychotic drug market share by region, 2015 & 2025
6.2 North America
6.2.1 North America Antipsychotic drugs market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. antipsychotic drugs market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Antipsychotic drugs market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe antipsychotic drugs market, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK antipsychotics drugs market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Antipsychotics drugs market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific antipsychotic drugs market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan antipsychotic drugs market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China antipsychotics drugs market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America antipsychotic drugs market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil antipsychotic drugs market, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico antipsychotic drug market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA Antipsychotic drug market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Antipsychotic drug market, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Johnson & Johnson
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Geographic foothold
7.1.1.4 Product benchmarking
7.1.1.5 Strategic initiatives
7.1.2 Pfizer, Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Geographic foothold
7.1.2.4 Product benchmarking
7.1.2.5 Strategic initiatives
7.1.3 Eli Lilly & Co.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Geographic foothold
7.1.3.4 Product benchmarking
7.1.3.5 Strategic initiatives
7.1.4 Bristol-Myers Squibb Company
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Geographic foothold
7.1.4.4 Product benchmarking
7.1.4.5 Strategic initiatives
7.1.5 AstraZeneca
7.1.5.1 Company overview
7.1.5.2 Financial Performance
7.1.5.3 Geographic foothold
7.1.5.4 Product benchmarking
7.1.5.5 Strategic initiatives
7.1.6 Glaxo SmithKline, Plc
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Geographic foothold
7.1.6.4 Product benchmarking
7.1.6.5 Strategic initiatives
7.1.7 Allergan
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Geographic foothold
7.1.7.4 Product benchmarking
7.1.7.5 Strategic initiatives
1.1 Information Procurement
1.2 Data Analysis
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 ANTIPSYCHOTIC DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Growing prevalence of psychosis and associated disorders
3.1.1.2 Continuous investment in research and development
3.1.2 Market restraint analysis
3.1.2.1 Adverse effects and chance of habit formation
3.1.2.2 Patent expiry of major drugs
3.2 Penetration & Growth Prospect Mapping, 2016
3.3 Antipsychotics Drugs Market- PESTLE Analysis, 2016
3.4 Industry Analysis - Porter’s, 2016
3.5 Pipeline Analysis of Antipsychotic Drugs
CHAPTER 4 ANTIPSYCHOTIC DRUGS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1 Antipsychotic Drug Market: Drug Class Movement Analysis, 2016
4.2 First Generation/Standard/Typical Antipsychotics Drug
4.2.1 First generation/Standard/Typical antipsychotic drugs market estimates & forecasts, 2014 - 2025 (USD Million)
4.3 Haldol market
4.3.1 Haldol market estimates & forecasts, 2014 - 2025 (USD Million)
4.4 Navane market
4.4.1 Navane market estimates & forecasts, 2014 - 2025 (USD Million)
4.5 Other market
4.5.1 Other market estimates & forecasts, 2014 - 2025 (USD Million)
4.6 Second Generation/Atypical Antipsychotics Drug
4.6.1 Second generation/Atypical antipsychotic drugs market market estimates & forecasts, 2014 - 2025 (USD Million)
4.7 Zyprexa market
4.7.1 Zyprexa market estimates & forecasts, 2014 - 2025 (USD Million)
4.8 Seroquel market
4.8.1 Seroquel market estimates & forecasts, 2014 - 2025 (USD Million)
4.9 Risperdal market
4.9.1 Risperdal market estimates & forecasts, 2014 - 2025 (USD Million)
4.10 Invega market
4.10.1 Invega market estimates & forecasts, 2014 - 2025 (USD Million)
4.11 Latuda market
4.11.1 Latuda market estimates & forecasts, 2014 - 2025 (USD Million)
4.12 Others market
4.12.1 Other market estimates & forecasts, 2014 - 2025 (USD Million)
4.13 Third generation Antipsychotics Drug
4.13.1 Third generation antipsychotic drugs market, 2014 - 2025 (USD Million)
CHAPTER 5 ANTIPSYCHOTIC DRUGS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Antipsychotics Drugs Market: Application Movement Analysis, 2016
5.2 Schizophrenia
5.2.1 Schizophrenia market estimates & forecasts, 2014 - 2025 (USD Million)
5.3 Bipolar Disorder
5.3.1 Bipolar Disorder market estimates & forecasts, 2014 - 2025 (USD Million)
5.4 Depression
5.4.1 Depression market estimates & forecasts, 2014 - 2025 (USD Million)
5.5 Dementia
5.5.1 Dementia market estimates & forecasts, 2014 - 2025 (USD Million)
5.6 Other psychotic disorders
5.6.1 Other psychotic disorders market estimates & forecasts, 2014 - 2025 (USD Million)
CHAPTER 6 ANTIPSYCHOTIC DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY DRUG CLASS AND APPLICATION
6.1 Antipsychotic drug market share by region, 2015 & 2025
6.2 North America
6.2.1 North America Antipsychotic drugs market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. antipsychotic drugs market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Antipsychotic drugs market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe antipsychotic drugs market, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK antipsychotics drugs market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Antipsychotics drugs market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific antipsychotic drugs market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan antipsychotic drugs market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China antipsychotics drugs market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America antipsychotic drugs market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil antipsychotic drugs market, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico antipsychotic drug market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA Antipsychotic drug market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Antipsychotic drug market, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Johnson & Johnson
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Geographic foothold
7.1.1.4 Product benchmarking
7.1.1.5 Strategic initiatives
7.1.2 Pfizer, Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Geographic foothold
7.1.2.4 Product benchmarking
7.1.2.5 Strategic initiatives
7.1.3 Eli Lilly & Co.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Geographic foothold
7.1.3.4 Product benchmarking
7.1.3.5 Strategic initiatives
7.1.4 Bristol-Myers Squibb Company
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Geographic foothold
7.1.4.4 Product benchmarking
7.1.4.5 Strategic initiatives
7.1.5 AstraZeneca
7.1.5.1 Company overview
7.1.5.2 Financial Performance
7.1.5.3 Geographic foothold
7.1.5.4 Product benchmarking
7.1.5.5 Strategic initiatives
7.1.6 Glaxo SmithKline, Plc
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Geographic foothold
7.1.6.4 Product benchmarking
7.1.6.5 Strategic initiatives
7.1.7 Allergan
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Geographic foothold
7.1.7.4 Product benchmarking
7.1.7.5 Strategic initiatives
LIST OF TABLES
TABLE 1 North America Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 2 North America antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 3 North America antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 4 North America antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 5 U.S. Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 6 U.S. Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 7 U.S. Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 8 U.S. Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 9 Canada Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 10 Canada Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 11 Canada Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 12 Canada Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 13 Europe Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 14 Europe Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 15 Europe Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 16 Europe Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 17 U.K Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 18 U.K Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 19 U.K Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 20 U.K Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 21 Germany Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 22 Germany Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 23 Germany Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 24 Germany Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 25 Asia Pacific Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 26 Asia Pacific Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 27 Asia Pacific Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 28 Asia Pacific Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 29 Japan Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 30 Japan Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 31 Japan Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 32 Japan Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 33 China Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 34 China Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 35 China Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 36 China Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 37 Latin America Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 38 Latin America Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 39 Latin America Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 40 Latin America Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 41 Brazil Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 42 Brazil Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 43 Brazil Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 44 Brazil Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 45 Mexico Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 46 Mexico Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 47 Mexico Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 48 Mexico Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 49 MEA Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 50 MEA Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 51 MEA Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 52 MEA Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 53 South Africa Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 54 South Africa Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 55 South Africa Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 56 South Africa Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 1 North America Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 2 North America antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 3 North America antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 4 North America antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 5 U.S. Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 6 U.S. Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 7 U.S. Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 8 U.S. Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 9 Canada Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 10 Canada Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 11 Canada Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 12 Canada Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 13 Europe Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 14 Europe Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 15 Europe Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 16 Europe Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 17 U.K Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 18 U.K Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 19 U.K Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 20 U.K Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 21 Germany Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 22 Germany Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 23 Germany Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 24 Germany Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 25 Asia Pacific Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 26 Asia Pacific Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 27 Asia Pacific Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 28 Asia Pacific Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 29 Japan Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 30 Japan Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 31 Japan Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 32 Japan Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 33 China Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 34 China Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 35 China Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 36 China Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 37 Latin America Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 38 Latin America Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 39 Latin America Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 40 Latin America Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 41 Brazil Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 42 Brazil Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 43 Brazil Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 44 Brazil Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 45 Mexico Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 46 Mexico Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 47 Mexico Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 48 Mexico Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 49 MEA Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 50 MEA Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 51 MEA Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 52 MEA Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
TABLE 53 South Africa Antipsychotic drugs market, by drug class, 2014 - 2025 (USD Million)
TABLE 54 South Africa Antipsychotic drugs market, by first generation, 2014 - 2025 (USD Million)
TABLE 55 South Africa Antipsychotic drug market, by second generation, 2014 - 2025 (USD Million)
TABLE 56 South Africa Antipsychotic drug market, by application, 2014 - 2025 (USD Million)
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends& outlook
FIG. 9 Market segmentation& scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Antipsychotics Drugs Market PESTLE Analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Antipsychotic drugs market drug class outlook key takeaways
FIG. 16 Antipsychotics drug market: Drug class movement analysis
FIG. 17 First generation/Standard/ Typical antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 18 Haldol market, 2014 - 2025 (USD Million)
FIG. 19 Navane market, 2014 - 2025 (USD Million)
FIG. 20 Other antipsychotic market, 2014 - 2025 (USD Million)
FIG. 21 Second generation/Atypical antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 22 Zyprexa market, 2014 - 2025 (USD Million)
FIG. 23 Seroquel market, 2014 - 2025 (USD Million)
FIG. 24 Risperdal market, 2014 - 2025 (USD Million)
FIG. 25 Invega market, 2014 - 2025 (USD Million)
FIG. 26 Latuda market, 2014 - 2025 (USD Million)
FIG. 27 Other second-generation market, 2014 - 2025 (USD Million)
FIG. 28 Third generation antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 29 Antipsychotic drugs market application outlook key takeaways
FIG. 30 Antipsychotics drug market: Application movement analysis
FIG. 31 Global Schizophrenia market, 2014 - 2025 (USD Million)
FIG. 32 Global Bipolar Disorder market, 2014 - 2025 (USD Million)
FIG. 33 Global depression market, 2014 - 2025 (USD Million)
FIG. 34 Global dementia market, 2014 - 2025 (USD Million)
FIG. 35 Global other psychotic disorders market, 2014 - 2025 (USD Million)
FIG. 36 Regional market place: Key takeaways
FIG. 37 Regional outlook, 2015 & 2024
FIG. 38 North America antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 39 U.S. antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 40 Canada antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 41 Europe antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 42 UK antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 43 Germany antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 44 Asia Pacific antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 45 Japan antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 46 China antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 47 Latin America antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 48 Brazil antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 49 Mexico antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 50 MEA antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 51 South Africa antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 52 Global presence of Johnson & Johnson
FIG. 53 Global presence of Pfizer, Inc.
FIG. 54 Global presence of Eli Lilly &Co.
FIG. 55 Global presence of Bristol Meyer Squibb Company
FIG. 56 Global presence of AstraZeneca
FIG. 57 Global presence of Glaxo SmithKline, Plc
FIG. 58 Global presence of Allergan
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends& outlook
FIG. 9 Market segmentation& scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Antipsychotics Drugs Market PESTLE Analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Antipsychotic drugs market drug class outlook key takeaways
FIG. 16 Antipsychotics drug market: Drug class movement analysis
FIG. 17 First generation/Standard/ Typical antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 18 Haldol market, 2014 - 2025 (USD Million)
FIG. 19 Navane market, 2014 - 2025 (USD Million)
FIG. 20 Other antipsychotic market, 2014 - 2025 (USD Million)
FIG. 21 Second generation/Atypical antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 22 Zyprexa market, 2014 - 2025 (USD Million)
FIG. 23 Seroquel market, 2014 - 2025 (USD Million)
FIG. 24 Risperdal market, 2014 - 2025 (USD Million)
FIG. 25 Invega market, 2014 - 2025 (USD Million)
FIG. 26 Latuda market, 2014 - 2025 (USD Million)
FIG. 27 Other second-generation market, 2014 - 2025 (USD Million)
FIG. 28 Third generation antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 29 Antipsychotic drugs market application outlook key takeaways
FIG. 30 Antipsychotics drug market: Application movement analysis
FIG. 31 Global Schizophrenia market, 2014 - 2025 (USD Million)
FIG. 32 Global Bipolar Disorder market, 2014 - 2025 (USD Million)
FIG. 33 Global depression market, 2014 - 2025 (USD Million)
FIG. 34 Global dementia market, 2014 - 2025 (USD Million)
FIG. 35 Global other psychotic disorders market, 2014 - 2025 (USD Million)
FIG. 36 Regional market place: Key takeaways
FIG. 37 Regional outlook, 2015 & 2024
FIG. 38 North America antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 39 U.S. antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 40 Canada antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 41 Europe antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 42 UK antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 43 Germany antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 44 Asia Pacific antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 45 Japan antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 46 China antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 47 Latin America antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 48 Brazil antipsychotic drugs market, 2014 - 2025 (USD Million)
FIG. 49 Mexico antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 50 MEA antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 51 South Africa antipsychotic drug market, 2014 - 2025 (USD Million)
FIG. 52 Global presence of Johnson & Johnson
FIG. 53 Global presence of Pfizer, Inc.
FIG. 54 Global presence of Eli Lilly &Co.
FIG. 55 Global presence of Bristol Meyer Squibb Company
FIG. 56 Global presence of AstraZeneca
FIG. 57 Global presence of Glaxo SmithKline, Plc
FIG. 58 Global presence of Allergan
